- 790,000 deaths: Klebsiella pneumoniae caused approximately 790,000 deaths globally in 2019.
- 40% of neonatal sepsis deaths: The pathogen is responsible for up to 40% of neonatal sepsis deaths in low-income countries.
- Zero licensed vaccines: There are currently no licensed vaccines available for K. pneumoniae.
Experts would likely conclude that this partnership represents a significant step forward in addressing antimicrobial resistance by leveraging synthetic biology to overcome the historical challenges of Klebsiella pneumoniae vaccine development.
Delonix and A*STAR Partner to Hack Klebsiella's Vaccine Defenses
SHANGHAI and SINGAPORE – November 16, 2026 — In the escalating arms race between modern medicine and antimicrobial resistance (AMR), the bacteria are currently winning. But a newly announced public-private partnership is attempting to rewrite the rules of engagement by turning one of the world's most dangerous pathogens against itself.
Delonix Bioworks, a clinical-stage biotechnology company operating out of Shanghai and Singapore, has finalized a Research Collaboration Agreement with A*STAR Infectious Diseases Labs (IDL), a premier research institute under Singapore's Agency for Science, Technology and Research. The alliance, announced today, aims to discover and develop novel outer membrane vesicle (OMV) vaccine candidates targeting Klebsiella pneumoniae—a pathogen the World Health Organization (WHO) classifies as a critical-priority threat due to its staggering levels of multi-drug and carbapenem resistance.
For investors and pharmaceutical strategists, this collaboration represents more than just early-stage pipeline expansion. It highlights a critical operational innovation in vaccine development: the use of synthetic biology to bypass the physical and genetic defenses that have historically made Klebsiella pneumoniae an elusive target.
The Klebsiella Enigma and the Capsular Shield
To understand the strategic rationale behind this collaboration, one must first understand the biological fortress that is Klebsiella pneumoniae.
K. pneumoniae is a leading cause of life-threatening pneumonia, bloodstream infections, and sepsis. It is particularly devastating in hospital settings and among vulnerable populations. According to global health data, the pathogen was associated with roughly 790,000 deaths in 2019 alone and is responsible for up to 40% of neonatal deaths due to sepsis in low-income countries.
Despite this massive public health burden, there are currently zero licensed vaccines available globally. The failure to develop a preventative countermeasure is not for lack of trying. Traditional vaccine approaches have been repeatedly thwarted by the bacterium's extensive genetic diversity and its primary defense mechanism: a thick coat of capsular polysaccharides.
This capsule acts as a biological cloaking device, masking conserved surface antigens from the host's immune system. Furthermore, the sheer variety of capsular serotypes means that a vaccine designed to target the polysaccharide coat of one strain will likely fail against another.
"The historical graveyard of Klebsiella vaccine candidates is largely populated by polysaccharide-based formulations that couldn't overcome the hurdle of serotype variability," noted one independent vaccinologist familiar with the AMR landscape. "To get broad cross-strain protection, you have to look beneath the capsule, but accessing those conserved antigens without triggering toxic shock has been the ultimate biophysical hurdle."
Engineering a Trojan Horse: The OMV Plus Platform
This is where Delonix Bioworks’ proprietary OMV Plus platform enters the equation, offering a highly differentiated, engineered solution to the capsular masking problem.
Outer membrane vesicles (OMVs) are naturally occurring, non-replicating nanoparticles that pinch off from the outer membrane of Gram-negative bacteria. Because they naturally possess pathogen-associated molecular patterns (PAMPs), OMVs act as potent adjuvants, stimulating both innate and adaptive immune responses. However, native OMVs come with a fatal flaw: they are laden with lipopolysaccharide (LPS), a potent endotoxin that causes severe reactogenicity and systemic inflammation in humans.
Delonix's operational innovation lies in its precise bacterial genome editing. Through the OMV Plus platform, the company genetically engineers the source bacteria to achieve three critical modifications. First, it detoxifies the endotoxins, creating an "LPS-null" or highly attenuated profile that dramatically improves the safety and tolerability of the vesicles. Second, it modulates capsular interference, effectively stripping away the thick polysaccharide shield that masks underlying targets. Finally, it enriches conserved native antigens on the surface of these non-replicating vesicles.
By editing the pathogen's genome to produce safe, highly immunogenic vesicles that display universally conserved antigens, Delonix is essentially manufacturing a highly programmable bionanomaterial platform.
The technical feasibility of this approach is already being validated in the clinic. Delonix’s lead asset, DX-104—an engineered OMV vaccine targeting Meningococcal Group B (MenB)—is currently undergoing Phase I clinical trials. Having received Investigational New Drug (IND) clearance from China's National Medical Products Administration and ethics approval in Australia, first-in-human dosing commenced earlier this year. The ability of DX-104 to induce robust serum bactericidal antibody responses without external adjuvants in preclinical models provides a strong proof-of-concept for the platform's application to K. pneumoniae.
Singapore's Strategic Biotech Frontline
While Delonix brings the synthetic biology engine, A*STAR IDL provides the navigational instruments required to steer these candidates through the complex landscape of infectious disease translation.
Established in April 2021 in the wake of the COVID-19 pandemic, A*STAR IDL was designed to position Singapore as a global hub for epidemic preparedness and applied AMR innovation. The institute operates state-of-the-art BSL-3 high-containment facilities and houses interdisciplinary experts focused on moving beyond mere pathogen surveillance toward deployable, scalable medical interventions.
Crucially for Delonix, A*STAR IDL provides access to clinically relevant, locally sourced bacterial isolates. Vaccine candidates engineered in a vacuum often fail when confronted with real-world, hypervirulent clinical lineages. By screening Delonix's engineered OMVs against A*STAR’s repository of circulating, drug-resistant K. pneumoniae strains, the partnership ensures that the resulting vaccine is optimized for the actual threats facing hospital networks today.
A*STAR IDL will also spearhead the specialized immunological evaluation of the vaccine candidates, assessing safety, immunogenicity, and broad cross-strain protective potential. This division of labor reflects a highly efficient public-private partnership model. It allows Delonix to leverage sovereign-level research infrastructure while enabling Singapore to advance its national health security mandate against an escalating regional and global threat.
Navigating the Competitive Landscape
The Delonix-A*STAR alliance emerges within a heating competitive landscape for K. pneumoniae interventions. With antibiotic pipelines running dry, preventative immunology is drawing significant capital.
Several alternative strategies are currently in development across the sector. For instance, Vaxdyn is advancing K-Vax, an inactivated whole-cell vaccine based on Acinetobacter baumannii engineered to display conserved Klebsiella antigens, which is approaching human trials. Meanwhile, bioconjugate vaccines, such as the tetravalent Kleb4V targeting predominant O-antigen serotypes, are already in Phase I studies.
However, engineered OMVs offer distinct manufacturing and biological advantages. Unlike complex bioconjugates that can be expensive and difficult to scale, OMVs are highly scalable and exhibit remarkable stability under various environmental conditions. Delonix has already demonstrated commercial-scale production with high batch-to-batch consistency for its DX-104 program, a de-risking factor that will likely appeal to future commercialization partners or licensing entities.
The financial terms of the Delonix and A*STAR IDL Research Collaboration Agreement remain undisclosed. Yet, the strategic intent is clear. Delonix has a track record of utilizing flexible partnership models to maximize pipeline value, and this co-discovery framework allows the biotech firm to aggressively expand its portfolio without burning excessive internal capital on early-stage immunological screening.
As the WHO warns of widespread and accelerating resistance to common antibiotics, the traditional pharmaceutical playbook of developing novel small-molecule bactericidals is proving scientifically and economically unsustainable. The path forward requires operational innovation at the intersection of synthetic biology and immunology. By reprogramming the very architecture of a deadly pathogen to serve as its own vaccine, Delonix Bioworks and A*STAR IDL are not just chasing a lucrative market opportunity; they are attempting to build a scalable template for the future of antimicrobial defense.
Topics & Related
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →